Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia

首页> 外文期刊>Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur? Transfusionsmedizin und Immunham?atologie >Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia

【24h】

Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia

机译：Bristol Myers Squibb获得欧洲委员会对Luspatercept的批准（Reblozyl（R））治疗成人患者与MDS疾病或β脑血症相关的输血依赖性贫血患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur? Transfusionsmedizin und Immunham?atologie》 |2020年第4期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
入库时间 2022-08-20 07:38:21

相似文献

外文文献
中文文献
专利

1. Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia [J] . Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur? Transfusionsmedizin und Immunham?atologie . 2020,第4期

机译：Bristol Myers Squibb获得欧洲委员会对Luspatercept的批准（Reblozyl（R））治疗成人患者与MDS疾病或β脑血症相关的输血依赖性贫血患者
2. Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from FDA [J] . Journal of drugs in dermatology: JDD . 2015,第2期

机译：百时美施贵宝（Bristol-Myers Squibb）获得FDA对Opdivo（nivolumab）的加速批准
3. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia [J] . Cappellini M. D., Viprakasit V., Taher A. T., The New England journal of medicine . 2020,第13期

机译：输血依赖性β-Thalassemia患者的Luspatercept的3阶段试验
4. Indicators of male fertility potential in adult patients with beta-thalassemia major: a comparative study between patients undergone allogeneic stem cell transplantation and transfusion-dependent patients [O] . Tahereh Rostami, Mohammad Amir Mohammadifard, Shahla Ansari, 2020

机译：成人重型β地中海贫血患者中男性生育能力的指标：同种异体干细胞移植患者与输血依赖患者之间的比较研究
5. Do guidelines preclude hepatitis B patients from receiving treatment? Potential conflict of interest: Dr. Lok is a consultant for and received grants from Gilead and Schering-Plough. She is also a consultant for Roche and received grants from Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. [O] . Degertekin Bulent, Lok Anna S. 2009

机译：指南是否阻止乙型肝炎患者接受治疗？潜在的利益冲突：Lok博士是Gilead和先灵葆雅的顾问，并获得了资助。她还是罗氏的顾问，并获得了Bristol-myers squibb，GlaxosmithKline和Novartis的资助。

Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia

著录项

相似文献

相关主题

期刊订阅